Predicted to enable actin filament binding activity; beta-catenin binding activity; and identical protein binding activity. Predicted to be involved in several processes, including modification of postsynaptic actin cytoskeleton; negative regulation of Arp2/3 complex-mediated actin nucleation; and nervous system development. Predicted to be located in several cellular components, including basolateral plasma membrane; lamellipodium; and postsynaptic density. Predicted to be part of catenin complex. Predicted to be active in several cellular components, including hippocampal mossy fiber to CA3 synapse; parallel fiber to Purkinje cell synapse; and postsynaptic density, intracellular component. Predicted to be extrinsic component of postsynaptic membrane and extrinsic component of presynaptic membrane. Human ortholog(s) of this gene implicated in complex cortical dysplasia with other brain malformations. Orthologous to human CTNNA2 (catenin alpha 2); PARTICIPATES IN arrhythmogenic right ventricular cardiomyopathy pathway; endometrial cancer pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A; cadmium dichloride.
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ...
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...